Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZURE-CHINA
NCT06834932Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of laroprovstat in dyslipidemia (8 arms), sponsored by AstraZeneca. Primary endpoints: AZD0780 Concentrations in plasma at Day 29, Area under the plasma concentration-time curve from time zero to time t at Day 29 and 3 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
laroprovstat
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06834932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834932.